Learn More
BACKGROUND Resistance to antiretroviral agents remains a leading cause of treatment failure for patients infected with HIV-1. OBJECTIVE To describe the efficacy and safety of tenofovir disoproxil fumarate (tenofovir DF) compared with placebo in patients with detectable viral replication despite current antiretroviral therapy. DESIGN Randomized,(More)
TTL caching models have recently regained significant research interest, largely due to their ability to fit popular caching policies such as LRU. In this extended abstract we briefly describe our recent work on two <i>exact</i> methods to analyze TTL cache networks. The first method generalizes existing results for line networks under renewal requests to(More)
OBJECTIVE To evaluate the safety and efficacy of once daily doses of tenofovir DF (TDF) administered in combination with other antiretroviral therapy (ART) in treatment-experienced HIV-1-infected patients with incomplete virological suppression. DESIGN One-hundred and eighty-nine subjects with plasma HIV-1 RNA levels between 400 and 100,000 copies/ml and(More)
BACKGROUND We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive HIV-infected patients. METHODS Eligible patients with HIV-1 RNA (vRNA) levels >5000 copies per milliliter and without baseline resistance to efavirenz, tenofovir, or emtricitabine were randomized in a(More)
OBJECTIVE To evaluate the antiviral activity, safety, pharmacokinetics, and pharmacokinetics/pharmacodynamics of short-term monotherapy with tenofovir alafenamide (TAF), a next-generation tenofovir (TFV) prodrug. DESIGN A phase 1b, randomized, partially blinded, active- and placebo-controlled, dose-ranging study. METHODS Treatment-naive and experienced(More)
TTL caching models have recently regained significant research interest due to their connection to popular caching policies such as LRU. This paper advances the state-of-the-art analysis of TTL-based cache networks by developing two exact methods with orthogonal generality and computational complexity. The first method generalizes existing results for line(More)
BACKGROUND Use of raltegravir with optimum background therapy is effective and well tolerated in treatment-experienced patients with multidrug-resistant HIV-1 infection. We compared the safety and efficacy of raltegravir with efavirenz as part of combination antiretroviral therapy for treatment-naive patients. METHODS Patients from 67 study centres on(More)
BACKGROUND To reduce lipid abnormalities and other side-effects associated with antiretroviral regimens containing lopinavir-ritonavir, patients might want to switch one or more components of their regimen. We compared substitution of raltegravir for lopinavir-ritonavir with continuation of lopinavir-ritonavir in HIV-infected patients with stable viral(More)
BACKGROUND GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase. METHODS The antiviral activity, tolerability, pharmacokinetics, and pharmacodynamics of GS-9137 were evaluated in a randomized, double-blind, placebo-controlled monotherapy study in 40 HIV-1- infected patients not receiving antiretroviral therapy with an HIV-1 RNA(More)
BACKGROUND This phase 2, randomized, active-controlled, 48-week study assessed the noninferiority of the human immunodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator ritonavir-boosted protease inhibitor (CPI/r) in treatment-experienced subjects. METHODS Subjects had HIV RNA levels 1000 copies/mL and 1 protease resistance mutation.(More)